José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
Radiotherapy plans generated with machine learning in the RayStation system are now being used at the Princess Margaret Cancer Centre, in ... Read more
Delivering higher doses of radiation therapy over a shorter time period — an approach called stereotactic body radiation therapy (SBRT) — ... Read more
Add-on treatment with Erleada (apalutamide) lowers the risk of death by 25% in men on androgen deprivation therapy (ADT) for non-metastatic castration-resistant ... Read more
The U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of men with metastatic castration-sensitive prostate cancer (mCSPC), ... Read more
Adding the investigational oral therapy onvansertib to a regimen of Zytiga (abiraterone acetate) and prednisone overcomes resistance to Zytiga in men ... Read more
Men with metastatic castration-resistant prostate cancer (mCRPC) given Lynparza (olaparib), a breast and ovarian cancer treatment, went a clinically meaningful longer time ... Read more
The potential oral therapy TRC253 was well-tolerated and showed effectiveness in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), according ... Read more
Treatment with Xtandi (enzalutamide) and testosterone suppression prolonged the survival of men with metastatic hormone-sensitive prostate cancer in comparison with standard ... Read more
Four in 10 adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations respond to treatment with Zejula (niraparib), according to early ... Read more
